YM-155 Hydrochloride: Precise Small-Molecule Survivin Inhibitor for Cancer Research

Executive Summary: YM-155 hydrochloride is a potent, selective inhibitor of survivin, a key member of the inhibitor of apoptosis protein (IAP) family, with an IC50 of 0.54 nM in biochemical assays (APExBIO). It shows minimal activity against other IAP or BCL-2 proteins, offering specificity for survivin-driven pathways (Schwartz 2022, DOI). YM-155 robustly suppresses proliferation and induces apoptosis in diverse human cancer cell lines and xenograft models. The compound demonstrates efficacy in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and melanoma models. Solubility, stability, and workflow integration parameters are well-established for reproducible research outcomes.

Biological Rationale

Survivin (BIRC5) is the smallest member of the inhibitor of apoptosis protein (IAP) family and plays a central role in cancer cell survival and resistance to therapy. It is overexpressed in most human malignancies but shows limited expression in differentiated adult tissues (Schwartz 2022). Survivin inhibits caspase activation and promotes cell cycle progression, making it a strategic target for anti-cancer drug development. Inhibiting survivin disrupts the IAP pathway, leading to apoptosis and reduced tumor growth. Small-molecule survivin inhibitors such as YM-155 hydrochloride enable targeted apoptosis induction in cancer research models (Related review).

Mechanism of Action of YM-155 hydrochloride

YM-155 hydrochloride (also known as sepantronium bromide) is a synthetic small molecule that selectively suppresses survivin gene expression at the transcriptional level. The suppression is highly potent, with an IC50 of 0.54 nM in cell-based reporter assays (APExBIO). YM-155 does not significantly inhibit other IAP family members or BCL-2 proteins at comparable concentrations, minimizing off-target effects. Its action leads to downregulation of survivin protein, caspase activation, and induction of apoptosis. In preclinical models, this mechanism translates into reduced tumor cell proliferation and enhanced cell death (Schwartz 2022).

Evidence & Benchmarks

• YM-155 hydrochloride exhibits an IC50 of 0.54 nM for survivin inhibition in cell-based assays (APExBIO).
• Minimal activity against other IAP or BCL-2 proteins is observed at 100-fold higher concentrations (Schwartz 2022, DOI).
• Induces tumor regression in human cancer xenograft models, including NSCLC, melanoma, bladder, and breast cancers (Schwartz 2022, Table 3.2).
• Reduces spontaneous metastases and prolongs survival in TNBC metastatic models (Schwartz 2022, Section 4.4).
• Solubility: ≥19.45 mg/mL in DMSO, ≥4.34 mg/mL in ethanol (with warming/ultrasound), ≥48.1 mg/mL in water (ultrasound); stable at -20°C (APExBIO).

This article extends the protocol-focused guide at survivin-baculoviral-iap-repeat-containing-protein-5-21-28.com by providing updated quantitative benchmarks and workflow integration details. It also clarifies solubility and storage parameters absent from pd-l1.com, and provides mechanistic updates over the review at survivin.net.

Applications, Limits & Misconceptions

YM-155 hydrochloride is used exclusively for scientific research in cancer biology, apoptosis pathway studies, and xenograft tumor regression models. It is not approved for diagnostic or therapeutic use in humans. The compound is particularly advantageous for dissecting the inhibitor of apoptosis protein (IAP) pathway and evaluating anti-cancer drug responses in vitro and in vivo.

Common Pitfalls or Misconceptions

• Not a pan-IAP inhibitor: YM-155 is highly selective for survivin and does not inhibit XIAP, cIAP1/2, or BCL-2 family proteins at relevant doses (Schwartz 2022).
• Not for clinical use: Intended strictly for preclinical and in vitro research; not suitable for diagnostic or therapeutic applications (APExBIO).
• Solution stability: Aqueous or DMSO solutions are not recommended for long-term storage; prepare fresh prior to experiments (APExBIO).
• Solubility constraints: Solubility varies by solvent; use ultrasonic treatment for full dissolution in water or ethanol.
• Selective applicability: Efficacy is established in cancer cell lines and xenografts, but not validated for normal tissue or non-oncological models.

Workflow Integration & Parameters

YM-155 hydrochloride (APExBIO, SKU: A3947) is typically supplied as a solid. For in vitro studies, dissolve to ≥19.45 mg/mL in DMSO or ≥48.1 mg/mL in water (ultrasound). For animal studies, ensure complete dissolution and filter sterilization. Store solid at -20°C and avoid repeated freeze-thaw cycles. Recommended to prepare working solutions fresh for each experiment (APExBIO protocol). In proliferation or apoptosis assays, dose-response curves should be established for each cell line or model system. Positive controls (e.g., staurosporine) and vehicle controls (DMSO or saline) are essential for data normalization.

Conclusion & Outlook

YM-155 hydrochloride is a benchmark small-molecule survivin inhibitor, empowering researchers to interrogate the apoptosis pathway in advanced cancer models. Its nanomolar potency, selectivity, and well-characterized handling parameters make it an indispensable tool for preclinical oncology research. As new survivin-targeted strategies emerge, YM-155 remains a key standard for mechanism-of-action studies and comparative pharmacology. For detailed product information and procurement, visit the YM-155 hydrochloride product page from APExBIO.